The Lancet Oncology expands its content to include primary research
Journal well-positioned to attract highest quality contributions.
London, 1 November 2004 – In the tradition of its esteemed parent publication The Lancet, The Lancet Oncology will begin publishing peer-reviewed oncology research beginning in May 2005.
"This is the latest step in the continuing progression of The Lancet's family of journals, said The Lancet editor, Dr. Richard Horton. “We have launched three review journals since 2000 - The Lancet Oncology, The Lancet Neurology and The Lancet Infectious Diseases - which have all rapidly established themselves as 'must-read' journals for clinicians in their respective fields.”
The Lancet Oncology, which currently publishes informative reviews and analysis, is the first of The Lancet’s three review publications to begin accepting primary research. Its 'fast track' publication process will allow The Lancet Oncology to achieve early online publication of the most important research on The Lancet's portal, www.thelancet.com. Article publication can now be achieved in as little as four weeks from submission.
The addition of pr imary research to The Lancet Oncology will further enhance its reputation amongst oncologists.
The Lancet Oncology editor David Collingridge added, "The relaunch will occur in two phases - beginning with a major redesign in January 2005 prior to the inclusion of peer-reviewed research in May 2005. Recruitment of additional editorial staff commences immediately. We shall be issuing a 'call for papers' soon and look forward to working with authors to build what will be one of the world's leading oncology journals."
# # #
About The Lancet
Founded in 1823 by surgeon Thomas Wakley with a vision ‘to inform, to reform, and to entertain’, nearly 200 years later The Lancet’s vision remains unchanged. The journal is one of a select few weekly medical titles published worldwide which seeks to influence clinical practice by the publication of high-quality peer-reviewed research covering a broad spectrum of medical disciplines of appeal to clinical practitioners and research academics alike.
In addition to the publication of peer-reviewed research, the journal educates readers through a weekly seminar on a specific topic and regular review articles analysing the status of research in a particular field; regular obituaries and reviews of books, websites, and exhibitions and a lively correspondence section add to The Lancet’s vibrancy and colour. Available by print or online subscription, recent developments have seen the emergence of three monthly specialty review journals: The Lancet Oncology, The Lancet Infectious Diseases, and The Lancet Neurology. October 2003 heralded the arrival of 180 years of electronic Lancet archive material from ScienceDirect®.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com